CompletedPhase 2NCT02513095

Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)

Studying Exercise-induced malignant hyperthermia

Last synced from ClinicalTrials.gov May 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Eagle Pharmaceuticals, Inc.
Principal Investigator: Adrian Hepner, MD
Eagle Pharmaceuticals, Inc.
Intervention: Dantrolene sodium for injectable suspension(drug)
Enrollment: 34 enrolled
Eligibility: 18-45 years · All sexes
Timeline: 2015 – 2015

Study locations (1)

Mecca, Saudi Arabia

Collaborators

Quintiles, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02513095 on ClinicalTrials.gov

← Back to all trials